Updated:
CJNV BioVenture
CJNV BioVenture is a family office focused on biopharmaceutical investments, with a network of offices spanning Cambridge (MA), Pasadena (CA), San Francisco...
CJNV BioVenture
CJNV BioVenture is a family office focused on biopharmaceutical investments, with a network of offices spanning Cambridge (MA), Pasadena (CA), San Francisco (CA), Greenwich (CT), New York (NY), and Abu Dhabi (UAE). The firm's founding year and founding principals are not publicly disclosed. The investment strategy targets therapeutics, drug delivery, diagnostics, and life science tools, spanning preclinical through clinical-stage and commercial opportunities. CJNV typically participates in venture rounds and syndicated co-investments with other family offices, venture capital firms, and strategic pharmaceutical companies. The firm has taken positions in companies such as Keros Therapeutics (a clinical-stage biotech developing treatments for hematologic and musculoskeletal diseases) and other undisclosed private biotechs (public record). Its geographic footprint includes both the United States and the Middle East via the Abu Dhabi office. The size of CJNV's investment team and total assets under management remain private. The firm holds an office footprint that suggests a globally distributed team. A recent operational development is not verifiable from available sources. CJNV BioVenture differentiates itself through its distributed-office model spanning biotech hubs in the US and the Middle East, and its willingness to invest across the capital stack in life sciences. This structure allows it to operate with a private, family-controlled governance framework while maintaining close proximity to deal flow in major research centers.
General information
Firm type
Venture Capital
Year founded
2021
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Cambridge
Corporate office
Cambridge, United States
Additional offices
Pasadena, United States · Abu Dhabi, United Arab Emirates · San Francisco, United States · Greenwich, United States · New York, United States
Sector focus
Frequently asked questions
Who runs investment decisions at CJNV BioVenture?
The principals leading CJNV BioVenture are not publicly named. The firm maintains a low public profile, and its investment team composition is not disclosed in available sources.
What is CJNV BioVenture's investment strategy?
CJNV BioVenture focuses on therapeutics, pharmaceuticals, diagnostics, and life science tools. It invests across development stages from preclinical to commercial and participates in both venture rounds and syndicated co-investments.
Is CJNV BioVenture a single family office or does it operate like a venture firm?
CJNV BioVenture functions as a family office with a global geography. It does not appear to manage third-party capital as a venture firm, but it actively co-invests with institutional and strategic investors in biotech syndicates.
Does CJNV BioVenture participate in fund commitments or only direct deals?
Available records indicate CJNV BioVenture makes direct equity investments in private biotech companies. Its involvement in fund-of-funds or limited partner commitments is not publicly documented.
Which investment stages does CJNV BioVenture typically target?
CJNV BioVenture covers early (preclinical) to late-stage (commercial) opportunities in life sciences. It has participated in venture rounds for clinical-stage biotechs (public record).
What is CJNV BioVenture's known posture on co-investments alongside external GPs?
CJNV BioVenture co-invests alongside venture capital firms and strategic pharmaceutical investors in syndicated rounds. Its willingness to deploy capital in parallel with institutional GPs is consistent with typical family office behavior in biotech.
Does CJNV BioVenture maintain philanthropic structures?
No publicly available information links CJNV BioVenture to a charitable foundation or philanthropic entity.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: